{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:34:20Z","timestamp":1779302060545,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,10,14]],"date-time":"2005-10-14T00:00:00Z","timestamp":1129248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Colorectal cancer in primary sclerosing cholangitis patients with ulcerative colitis is mostly right\u2010sided where concentrations of carcinogenic secondary bile acids are highest.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To investigate whether ursodeoxycholic acid could be chemopreventive for colorectal cancer.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002A historical cohort study was performed on primary sclerosing cholangitis patients with ulcerative colitis where the 28 patients (cases) who were treated with ursodeoxycholic acid for at least 6\u2003months (mean 3.4\u2003\u00b1\u20032.7\u2003years) were compared with the 92 patients (controls) who were not treated with ursodeoxycholic acid. The primary outcomes were colorectal cancer and dysplasia. The secondary outcome was overall mortality.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002The cumulative incidence of dysplasia or cancer was not significantly different between cases and controls (<jats:italic>P<\/jats:italic>\u2003=\u20030.17 by log\u2010rank test). The adjusted relative risk for cases of developing dysplasia or cancer was 0.59 (95% CI 0.26\u20131.36). The cumulative mortality was significantly different between groups (<jats:italic>P<\/jats:italic>\u2003=\u20030.02 by log\u2010rank test). The adjusted relative risk for cases of death was 0.44 (95% CI 0.22\u20130.90).<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002In ulcerative colitis patients with primary sclerosing cholangitis, ursodeoxycholic acid did not reduce the risk of developing cancer or dysplasia. However, ursodeoxycholic acid may reduce mortality.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02650.x","type":"journal-article","created":{"date-parts":[[2005,10,14]],"date-time":"2005-10-14T13:32:36Z","timestamp":1129296756000},"page":"783-788","source":"Crossref","is-referenced-by-count":102,"title":["The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis"],"prefix":"10.1111","volume":"22","author":[{"given":"J. M.","family":"WOLF","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"RYBICKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. A.","family":"LASHNER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01156.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2420825"},{"key":"e_1_2_6_4_2","first-page":"85","article-title":"Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis","volume":"2","author":"Hill MJ","year":"1987","journal-title":"Lancet"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199703063361003"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00008"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50156"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03777.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.27965"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200008000-00009"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70215-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.149.1.6412283"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)32742-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90381-1"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(83)80175-0"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02650.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02650.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T21:01:26Z","timestamp":1693861286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02650.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,14]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02650.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02650.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,14]]}}}